Regulus Therapeutics Inc.
DelistedCIK 1505512fmd_097W90JPZE8Z731S4GDECR9269Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Mar 31, 2025, 58 periods
Latest annual · FY2021
Millions- Total revenues
- 0
- Operating income
- (50)
- Net income
- (46)
- Free cash flow
- (42)
Latest quarter · Q1 FY2025
Millions- Operating income
- (11)
- Net income
- (10)
- Free cash flow
- (11)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2019 to FY2024
- n/m
Regulus Therapeutics Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$50 million | -$31.1 million | 10-K 2025-03-13 · proof | |
| Net income | -$46.4 million | -$30 million | 10-K 2025-03-13 · proof | |
| Cash from operating activities | -$41.7 million | -$26.8 million | 10-K 2025-03-13 · proof | |
| Free cash flow | -$42 million | -$27.4 million | 10-K 2025-03-13 · proof | |
| Total assets | $84.2 million | $30.8 million | +173.8% | 10-K 2025-03-13 · proof |
| Total liabilities | $7.8 million | $9.6 million | -18.7% | 10-K 2025-03-13 · proof |
| Cash and cash equivalents | $38.5 million | $23.8 million | +62.1% | 10-K 2025-03-13 · proof |
- What was Regulus Therapeutics Inc.'s operating income in fiscal 2024?
- Regulus Therapeutics Inc. reported operating income of -$50 million for fiscal 2024 (the year ended Dec 31, 2024), against -$31.1 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What was Regulus Therapeutics Inc.'s net income in fiscal 2024?
- Regulus Therapeutics Inc. reported net income of -$46.4 million for fiscal 2024 (the year ended Dec 31, 2024), against -$30 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What was Regulus Therapeutics Inc.'s cash from operating activities in fiscal 2024?
- Regulus Therapeutics Inc. reported cash from operating activities of -$41.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$26.8 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What was Regulus Therapeutics Inc.'s free cash flow in fiscal 2024?
- Regulus Therapeutics Inc. reported free cash flow of -$42 million for fiscal 2024 (the year ended Dec 31, 2024), against -$27.4 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What are Regulus Therapeutics Inc.'s total assets?
- As of Dec 31, 2024, Regulus Therapeutics Inc. reported total assets of $84.2 million, against $30.8 million a year earlier (+173.8%). Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What are Regulus Therapeutics Inc.'s total liabilities?
- As of Dec 31, 2024, Regulus Therapeutics Inc. reported total liabilities of $7.8 million, against $9.6 million a year earlier (-18.7%). Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What are Regulus Therapeutics Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Regulus Therapeutics Inc. reported cash and cash equivalents of $38.5 million, against $23.8 million a year earlier (+62.1%). Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1505512&period_type=annual&limit=5"Information only, not investment advice.